Live Analyst Rating Changes 8690 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Leuchten
JEF
Michael Leuchten
Jefferies
Wall Street Analyst
★★★☆☆
#1259
on 13Foresight · ranked by our own returns
50%
Success Rate
-3.6%
Average Return
2 of 4 calls profitable · -1.9% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 50% of Michael Leuchten's ratings turned a profit when each position was held for 1 year — averaging -3.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

37 Buy 13 Hold 19 Sell
Michael's Stock Coverage 21 ratings · 2026-07-16
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
DE:BAYN
Bayer
 Jul 13, 2026 HOLD Strong Buy
+9.3% avg upside
28 analysts
$46.00
3.37% Downside
 ·
GB:AZN
AstraZeneca
 Jul 13, 2026 BUY Strong Buy
+17.9% avg upside
26 analysts
$17500.00
39.34% Upside
 ·
FR:SAN
Sanofi
 Jul 02, 2026 BUY Strong Buy
+29.4% avg upside
30 analysts
$100.00
31.22% Upside
 ·
GB:0QIU
Novo Nordisk
 Jun 30, 2026 HOLD Buy
+27.3% avg upside
29 analysts
$285.00
11.12% Downside
 ·
GB:0NZT
UCB SA
 Jun 22, 2026 SELL Buy
-3.7% avg upside
19 analysts
$212.00
8.97% Downside
 ·
CH:ROP
Roche Holding AG
 Jun 08, 2026 SELL Buy
+1.0% avg upside
23 analysts
$230.00
30.25% Downside
 ·
GB:GSK
GlaxoSmithKline
 Jun 03, 2026 BUY Hold
-1.1% avg upside
25 analysts
$2500.00
30.49% Upside
 ·
GSK
GlaxoSmithKline
 May 29, 2026 BUY Buy
-15.2% avg upside
19 analysts
$67.10
29.87% Upside
 +3.5%
CH:NOVN
Novartis AG
 Oct 04, 2023 HOLD Buy
-11.3% avg upside
31 analysts
$90.00
26.16% Downside
 ·
DE:SRT3
Sartorius
 Aug 21, 2023 BUY Buy
+11.4% avg upside
18 analysts
$470.00
89.92% Upside
 ·
DE:MRK
Merck KGaA
 Aug 04, 2023 BUY Buy
-2.9% avg upside
33 analysts
$208.00
48.52% Upside
 ·
FR:IPN
Ipsen
 Jun 30, 2023 HOLD Buy
-22.8% avg upside
17 analysts
$113.00
29.69% Downside
 ·
FR:DIM
Sartorius Stedim Biotech
 Jun 19, 2023 BUY Strong Buy
+32.4% avg upside
11 analysts
$390.00
106.36% Upside
 ·
GB:SHEL
Shell (UK)
 Oct 10, 2022 BUY Strong Buy
+480.2% avg upside
24 analysts
$2650.00
15.24% Downside
 ·
NVO
Novo Nordisk
 Jun 28, 2022 SELL Buy
+131.7% avg upside
26 analysts
 — -46.7%
DE:SRT
Sartorius
 Feb 28, 2022 SELL Strong Buy
+88.8% avg upside
5 analysts
$400.00
101.19% Upside
 ·
DE:FME
Fresenius Medical Care AG & Co. KGaA
 Nov 04, 2021 BUY Buy
+21.3% avg upside
22 analysts
$80.00
89.95% Upside
 ·
DE:FRE
Fresenius SE & Co. KGaA
 Nov 02, 2021 HOLD Strong Buy
+22.9% avg upside
20 analysts
$45.00
7.79% Upside
 ·
CH:ALC
Alcon
 Aug 23, 2021 BUY Buy
+29.1% avg upside
35 analysts
$85.00
53.47% Upside
 ·
SNY
Sanofi
 May 12, 2016 BUY Strong Buy
+68.7% avg upside
20 analysts
 — +29.5%
NVS
Novartis
 Apr 22, 2016 HOLD Buy
-10.0% avg upside
24 analysts
 — -0.5%
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael Leuchten — Frequently Asked Questions
How accurate are Michael Leuchten's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Michael's ratings were profitable over a one-year hold, with an average return of -3.6% per rating, or -1.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Michael ranked on 13Foresight?
Michael Leuchten is currently ranked #1259 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on DE:BAYN, GB:AZN, FR:SAN, GB:0QIU, GB:0NZT, CH:ROP, GB:GSK, GSK, CH:NOVN, DE:SRT3, DE:MRK, FR:IPN and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.